Genetic Signatures shares a bittersweet moment as we bid farewell to Dr. John Melki, who has announced his decision to step down as CEO and Director after an illustrious 21 years of leadership. John possesses an extraordinary blend of qualities and skills that have not only inspired, but also motivated and guided our team through a…

A recent article published via Sharecafe discusses Genetic Signatures’ new syndromic EasyScreen™ targets for use in EU and US Markets. To read more Click link

Genetic Signatures’ CEO Dr John Melki will be presenting ShareCafe Micro/Small Cap “Hidden Gems” webinar to be held at 12.30 pm AEST on Friday, 12 February 2021. The webinar is free to join and participants are required to register in advance via the following link: https://us02web.zoom.us/webinar/register/WN_KHst7HftQdSiQwoL6y9ufg

Genetic Signatures Annual Report 2020 released. Click link for more information.

Genetic Signatures’ CEO Dr John Melki will be presenting ShareCafe Micro/Small Cap “Hidden Gems” webinar to be held at 12.30 pm AEST on Friday, 28 August 2020. The webinar is free to join and participants are required to register in advance via the following link: https://us02web.zoom.us/webinar/register/WN_Mjb04hQtSY-nlSbLqWlpSw

Genetic Signatures latest Investor Presentation released. Click link for more information.

Genetic Signatures latest Investor Presentation released. Click link for more information.

Genetic Signatures latest Investor Presentation released. Click link for more information.

A recent article published in Australia’s Sydney Morning Herald with Genetic Signatures’ CEO Dr. John Melki discusses how our novel 3baseTM technology utilised in our EasyScreenTM SARS-CoV-2 Detection Kit has assisted in the quick diagnosis of the virus amongst patients. For more on the article click link “It is ultimately saving lives’: Businesses respond to…